Search results
Results from the WOW.Com Content Network
Reverse payment patent settlements, also known as "pay-for-delay" agreements, [1] are a type of agreement that has been used to settle pharmaceutical patent infringement litigation (or threatened litigation), in which the company that has brought the suit agrees to pay the company it sued. That is, the patent holder pays the alleged infringer ...
By 2008 Glenmark was the fifth-biggest pharmaceutical company in India. [5] By 2011 the founder of the company was one of the richest men in India, [6] and Glenmark had worldwide sales of $778 million, a 37% increase over the last year's sales; the growth was driven by Glenmark's entry into the US and European generics markets. [7]
The following is a list of the 20 largest settlements reached between the United States Department of Justice and pharmaceutical companies from 2001 to 2013, ordered by the size of the total settlement. The settlement amount includes both the civil (False Claims Act) settlement and criminal fine.
German pharmaceutical and chemical company Merck KGaA will pay $280 million to settle a claim brought against a former subsidiary, Dey Pharma, regarding Medicare and Medicaid reimbursements, the U ...
They agreed to pay $29.3 million. [19] In 2005, Medco Health Solutions agreed to pay the United States $155 million plus interest to settle allegations that it accepted kickbacks from drug makers and submitted false claims to the government. [20] There was no admission of guilt or finding of wrongdoing in either settlement.
Members of the family who own OxyContin maker Purdue Pharma, and the company itself, agreed to pay up to $7.4 billion in a new settlement to lawsuits over the toll of the powerful prescription ...
Blue Cross Blue Shield will soon begin paying out $2.67 billion to customers follow a years-long lawsuit alleging that the health insurance giant broke antitrust laws.. The litigation began in ...
J&J would pay fines and civil damages totaling about $1.3 billion. The numbers were still in flux and might go up or down a bit, but that was the target everyone was focused on. And, per the usual playbook, the company would plead guilty to one misdemeanor.